Safety of first trimester exposure to H2 blockers.
Lagace
E
E
University of Minnesota, Minneapolis, USA. lagac001@gold.tc.umn.edu
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D005260:Female; D006635:Histamine H2 Antagonists / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D011247:Pregnancy; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First; D011297:Prenatal Exposure Delayed Effects; D011446:Prospective Studies; D011899:Ranitidine / Q000009:adverse effects*; D015203:Reproducibility of Results; D012306:Risk
D006635:Histamine H2 Antagonists; D011899:Ranitidine